Skip to main content

Table 4 Top 10 adverse effects (grade 3–5) associated with gefitinib versus erlotinib

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Grade 3–5 Adverse effects Gefitinib group (event/total) Erlotinib group (event/total) RR (95% CI) P value Heterogeneity
I2 (%) P value
Skin rash 72/999 163/745 0.22 (0.12–0.41) < 0.00001 73 0.0006
Diarrhea 31/892 38/710 0.46 (0.29–0.74) 0.001 0 0.46
Nausea/Vomiting 8/639 27/531 0.23 (0.11–0.49) 0.0001 20 0.29
Fatigue 18/639 40/531 0.28 (0.09–0.87) 0.03 74 0.02
Anorexia 3/403 4/310 0.25 (0.06–1.04) 0.06 NA NA
Interstitial lung disease 7/619 3/514 1.05 (0.27–4.06) 0.95 17 0.3
Stomatitis 3/260 8/169 0.28 (0.08–0.99) 0.05 24 0.27
Elevated liver enzymes 80/652 23/400 1.50 (0.97–2.31) 0.07 0 0.64
Infection 9/454 7/380 1.12 (0.46–2.69) 0.8 20 0.28
Neutropenia 2/399 3/379 0.67 (0.11–3.97) 0.66 NA NA